We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Hologic to Buy Gen-Probe for USD 3.72 Billion

By LabMedica International staff writers
Posted on 11 Feb 2013
Hologic (Bedford, MA, USA) announced that it will buy Gen-Probe (San Diego, CA, USA) in an all-cash deal valued at USD 3.72 billion. More...
The purchase will allow Hologic to expand its growing diagnostics products and services business. The transaction is expected to close in the second half of the year (2013) and should result in USD 75 million in cost savings in its first three years, the companies said.

Hologic has been steadily building its diagnostics business, domestically and abroad. Last year, it acquired TCT International, a Chinese distributor of medical products, for USD 135 million in cash. The diagnostics business is one of the company’s fastest growing segments, according to Hologic’s second-quarter earnings report. For the six months ended March 24, the unit’s sales rose 10.3% from the period a year earlier. Hologic attributed the gain to growth in ThinPrep, its Pap test product. Hologic, Inc. is a leading developer, manufacturer, and supplier of premium diagnostic products, medical imaging systems, and surgical products. The company operates four core business units focused on diagnostics, breast health, GYN surgical and skeletal health.

Gen-Probe is a maker of molecular diagnostics products that are used to screen for blood diseases and test transplant compatibility, among other things. The combined businesses expect to generate annual revenue of about USD 2.4 billion.

“Gen-Probe is an ideal partner and strategic fit to Hologic’s existing diagnostics business and complements our focus on scaling and diversifying our diagnostics franchise,” Robert A. Cascella, the chief executive of Hologic, said in a statement. “Our combined company will be well positioned globally to capitalize on the fast-growing molecular diagnostics market with an established global infrastructure.”

Related Links:

Hologic
Gen-Probe



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.